Nile intends to develop Cenderitide as an outpatient therapy to be delivered to acutely decompensated heart failure (ADHF) patients continuously for up to 90 days after discharge from the hospital.
Nile CEO Joshua Kazam said they are very pleased that the FDA has recognized Cenderitide’s potential to address an important unmet medical need for heart failure patients.